My HappyStock
Log in to track your learning progress.
Korean Companies
Find my preferred stocks →Compare companies across six criteria and explore businesses that fit your priorities.
068270
Celltrion, Inc. (068270)
Average score 7.6 B
Preference —
Celltrion (official corporate identity; trademark; Wikimedia Commons PD-textlogo)
Six company scores
Average score
Company growth9 / 10
New biosimilars drive rapid revenue growth
Profitability8 / 10
Higher-margin products and lower costs lift profits
Financial stability8 / 10
Strong cash flow, but borrowing has increased
Economic moat8 / 10
Own manufacturing, direct sales and regulatory expertise
Future outlook9 / 10
New therapies and expanding U.S. sales offer upside
Valuation4 / 10
A high earnings multiple limits valuation appeal
Editorial scores are for education, not audited financial metrics or investment advice.
Revenue by business
- Biopharmaceuticals 94.4%
Remsima, Zymfentra, Yuflyma and other biologics
- Chemical medicines and other 5.6%
Small-molecule drugs, including Godex
Revenue by region
- Europe 45.21%
- South Korea 27.39%
- North America 18.8%
- Asia (ex-Korea) 5.43%
- Latin America 3.17%
Key metrics
| Revenue CAGR (5 years) | 18% |
|---|---|
| Operating income CAGR (5 years) | 10% |
| Net income CAGR (5 years) | 14% |
| Operating margin (5-year avg.) | 28% |
| ROE (5-year avg.) | 8% |
| ROA (5-year avg.) | 6% |
| Beta (5 years) | - |
| MDD (5 years) | - |
| Payout ratio (5-year avg.) | 20% |
| P/E | 46x |
| Forward P/E | 33x |
| PEG | - |